Important predictor of mortality in patients with end-stage liver disease.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, H.J. | - |
dc.contributor.author | Lee, H.W. | - |
dc.date.available | 2019-05-29T03:37:12Z | - |
dc.date.issued | 2013-06 | - |
dc.identifier.issn | 2287-285X | - |
dc.identifier.issn | 2287-285X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/19831 | - |
dc.description.abstract | Prognosis is an essential part of the baseline assessment of any disease. For predicting prognosis of end-stage liver disease, many prognostic models were proposed. Child-Pugh score has been the reference for assessing the prognosis of cirrhosis for about three decades in end-stage liver disease. Despite of several limitations, recent large systematic review showed that Child-Pugh score was still robust predictors and it's components (bilirubin, albumin and prothrombin time) were followed by Child-Pugh score. Recently, Model for end-stage liver disease (MELD) score emerged as a modern alternative to Child-Pugh score. The MELD score has been an important role to accurately predict the severity of liver disease and effectively assess the risk of mortality. Due to several weakness of MELD score, new modified MELD scores (MELD-Na, Delta MELD) have been developed and validated. This review summarizes the current knowledge about the prognostic factors in end-stage liver disease, focusing on the role of Child-Pugh and MELD score. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Important predictor of mortality in patients with end-stage liver disease. | - |
dc.type | Article | - |
dc.identifier.doi | 10.3350/cmh.2013.19.2.105 | - |
dc.identifier.bibliographicCitation | Clinical and molecular hepatology, v.19, no.2, pp 105 - 115 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-84890760561 | - |
dc.citation.endPage | 115 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 105 | - |
dc.citation.title | Clinical and molecular hepatology | - |
dc.citation.volume | 19 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordPlus | bilirubin | - |
dc.subject.keywordPlus | creatinine | - |
dc.subject.keywordPlus | blood | - |
dc.subject.keywordPlus | end stage liver disease | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | international normalized ratio | - |
dc.subject.keywordPlus | mortality | - |
dc.subject.keywordPlus | pathology | - |
dc.subject.keywordPlus | prognosis | - |
dc.subject.keywordPlus | severity of illness index | - |
dc.subject.keywordPlus | survival rate | - |
dc.subject.keywordPlus | Bilirubin | - |
dc.subject.keywordPlus | Creatinine | - |
dc.subject.keywordPlus | End Stage Liver Disease | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | International Normalized Ratio | - |
dc.subject.keywordPlus | Prognosis | - |
dc.subject.keywordPlus | Severity of Illness Index | - |
dc.subject.keywordPlus | Survival Rate | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.